Taysha Gene Therapies Inc (NASDAQ: TSHA) on Friday, soared 3.18% from the previous trading day, before settling in for the closing price of $2.83. Within the past 52 weeks, TSHA’s price has moved between $1.05 and $3.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -63.99% annually for the last half of the decade. The company achieved an average annual earnings per share of 2.03%. With a float of $222.28 million, this company’s outstanding shares have now reached $272.73 million.
Taysha Gene Therapies Inc (TSHA) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Taysha Gene Therapies Inc is 18.52%, while institutional ownership is 87.00%. The most recent insider transaction that took place on Aug 21 ’25, was worth 162,604. In this transaction President and Head of R&D of this company sold 57,054 shares at a rate of $2.85, taking the stock ownership to the 1,165,289 shares. Before that another transaction happened on Aug 21 ’25, when Company’s CHIEF FINANCIAL OFFICER sold 54,491 for $2.85, making the entire transaction worth $155,299. This insider now owns 1,187,603 shares in total.
Taysha Gene Therapies Inc (TSHA) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.07 earnings per share (EPS) for the period topping the consensus outlook (set at -0.09) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.82% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Taysha Gene Therapies Inc (TSHA) is currently performing well based on its current performance indicators. A quick ratio of 12.48 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 98.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.7 million. That was inferior than the volume of 2.88 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 43.80%.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 85.39%, which indicates a significant increase from 53.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.16 in the past 14 days, which was lower than the 0.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.67, while its 200-day Moving Average is $2.15. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $2.97. Second resistance stands at $3.01. The third major resistance level sits at $3.10. If the price goes on to break the first support level at $2.83, it is likely to go to the next support level at $2.74. Assuming the price breaks the second support level, the third support level stands at $2.70.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
Market capitalization of the company is 796.56 million based on 272,795K outstanding shares. Right now, sales total 8,330 K and income totals -89,300 K. The company made 1,990 K in profit during its latest quarter, and -26,880 K in sales during its previous quarter.
